This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JNP Juniper Pharmaceuticals (JNP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Juniper Pharmaceuticals Stock (NASDAQ:JNP) 30 days 90 days 365 days Advanced Chart Get JNP alerts:Sign Up Key Stats Today's Range$11.45▼$11.5050-Day Range N/A52-Week Range$4.30▼$13.25Volume28,513 shsAverage Volume155,873 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Juniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Juniper Pharmaceuticals, Inc. markets Crinone, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. Its product candidates include JNP-0101, which is designed to deliver oxybutynin for the treatment of overactive bladder in women; JNP-0201, which contains natural progesterone and estradiol to be used for hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone for the prevention of preterm birth in women with a short cervical length. The company offers pharmaceutical product development; clinical trial manufacturing; and analytical and consulting services. Juniper Pharmaceuticals, Inc. has collaboration agreements with Merck KGaA and Allergan, as well as patent license agreement with Massachusetts General Hospital. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts. Read More Receive JNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Juniper Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JNP Stock News HeadlinesJuniper Networks invests in AI startup Recogni in $102 million funding roundNovember 13, 2024 | reuters.comAnalysts’ Opinions Are Mixed on These Technology Stocks: Viavi Solutions (VIAV), Silicon Laboratories (SLAB) and Juniper Networks (JNPR)November 1, 2024 | markets.businessinsider.comWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re quietly shipping 30 tons per year from a facility outside San Antonio.August 2 at 2:00 AM | True Market Insiders (Ad)Juniper beats quarterly estimates on networking gear demandOctober 31, 2024 | reuters.comJuniper Networks revenue misses estimates on weak client spendingJanuary 30, 2024 | msn.comWhy Juniper Networks Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving PremarketJanuary 9, 2024 | msn.comJuniper Networks Stock (NYSE:JNPR), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comJuniper Essential Oil Market : Reliable Business Data Analysis and Forecast by 2028 with Top Countries DataOctober 20, 2022 | marketwatch.comSee More Headlines JNP Stock Analysis - Frequently Asked Questions How were Juniper Pharmaceuticals' earnings last quarter? Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) issued its earnings results on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.18. The specialty pharmaceutical company had revenue of $15.31 million for the quarter, compared to analyst estimates of $16.30 million. What other stocks do shareholders of Juniper Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Juniper Pharmaceuticals investors own include Novavax (NVAX), Bristol Myers Squibb (BMY), Verastem (VSTM), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Rigel Pharmaceuticals (RIGL) and Synergy Pharmaceuticals (SGYP). Company Calendar Last Earnings8/09/2018Today8/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:JNP CIK821995 Webwww.juniperpharma.com Phone617-639-1500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:JNP) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Juniper Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Juniper Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.